FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898084985> ?p ?o ?g. }

• W2898084985 endingPage "S359" @default.
• W2898084985 startingPage "S358" @default.
• W2898084985 abstract "Osimertinib is a third-generation, CNS-active EGFR-TKI that potently and selectively inhibits both EGFR-TKI sensitizing and EGFR T790M resistance mutations. We report results from a second planned protocol, optimal interim analysis of the ongoing ASTRIS study (NCT02474355). Eligible patients receive osimertinib 80 mg once daily. Inclusion criteria: stage IIIB/IV T790M-positive non-small cell lung cancer (NSCLC); T790M status confirmed locally by validated test, not restricted by sample type; prior EGFR-TKI therapy received; WHO performance status (PS) 0−2; acceptable organ and bone marrow function and no history of interstitial lung disease (ILD) or QTc prolongation. Asymptomatic, stable CNS metastases are permitted. The primary efficacy outcome is overall survival (OS). From Sept 18, 2015, first patient in, to Oct 20 2017 data cut-off (DCO), 3014 patients were enrolled across 16 countries and received ≥1 dose of osimertinib (full analysis set [FAS]): median follow-up 7.9 months (range <1−24), median age 62 yrs (27–92), 64% female, 69% Asian, 30% White, 11% WHO PS 2, 45% prior chemotherapy, 34% prior radiotherapy. All patients had T790M-positive status, identified from tissue in 1610 patients (53%), plasma ctDNA in 1241 patients (41%) and from other sources in 162 patients (5%). At DCO, 1276 patients (42%) had discontinued treatment (1738 [58%] ongoing); median duration of exposure 7.4 months (<1–25); 1289 patients (43%) had a progression-free survival (PFS) event, 1276 (42%) had a time to treatment discontinuation (TTD) event, and 593 (20%) had died. In patients evaluable for response, the investigator-assessed clinical response rate was 56.6% (1625/2872; 95% confidence interval [CI] 54.7, 58.4). In the FAS, estimated median PFS was 11.0 months (95% CI 10.6, 11.1), median TTD was 12.6 months (95% CI 12.2, 13.7), and median OS was not reached (OS at 12 months was 75.8% (95% CI 73.7, 77.8). Adverse events (AEs) leading to dose modification and treatment discontinuation were reported in 321 patients (11%) and 147 patients (5%), respectively. Serious AEs were reported in 505 patients (17%). ILD/pneumonitis-like events were reported in 41 patients (1%), and QTc prolongation in 48 patients (2%). ASTRIS, the largest reported study of osimertinib in T790M-positive NSCLC, demonstrates clinical activity similar to that observed in the osimertinib clinical trial program with no new safety signals." @default.
• W2898084985 created "2018-11-02" @default.
• W2898084985 creator A5013149755 @default.
• W2898084985 creator A5016050402 @default.
• W2898084985 creator A5020397680 @default.
• W2898084985 creator A5021704329 @default.
• W2898084985 creator A5034761732 @default.
• W2898084985 creator A5048183782 @default.
• W2898084985 creator A5055526321 @default.
• W2898084985 creator A5064998962 @default.
• W2898084985 creator A5069195930 @default.
• W2898084985 creator A5073440860 @default.
• W2898084985 creator A5075417603 @default.
• W2898084985 creator A5085449385 @default.
• W2898084985 creator A5085499011 @default.
• W2898084985 creator A5089732639 @default.
• W2898084985 date "2018-10-01" @default.
• W2898084985 modified "2023-09-25" @default.
• W2898084985 title "MA02.03 ASTRIS: A Real World Treatment Study of Osimertinib in Patients with EGFR T790M-Positive NSCLC" @default.
• W2898084985 doi "https://doi.org/10.1016/j.jtho.2018.08.324" @default.
• W2898084985 hasPublicationYear "2018" @default.
• W2898084985 type Work @default.
• W2898084985 sameAs 2898084985 @default.
• W2898084985 citedByCount "1" @default.
• W2898084985 countsByYear W28980849852019 @default.
• W2898084985 crossrefType "journal-article" @default.
• W2898084985 hasAuthorship W2898084985A5013149755 @default.
• W2898084985 hasAuthorship W2898084985A5016050402 @default.
• W2898084985 hasAuthorship W2898084985A5020397680 @default.
• W2898084985 hasAuthorship W2898084985A5021704329 @default.
• W2898084985 hasAuthorship W2898084985A5034761732 @default.
• W2898084985 hasAuthorship W2898084985A5048183782 @default.
• W2898084985 hasAuthorship W2898084985A5055526321 @default.
• W2898084985 hasAuthorship W2898084985A5064998962 @default.
• W2898084985 hasAuthorship W2898084985A5069195930 @default.
• W2898084985 hasAuthorship W2898084985A5073440860 @default.
• W2898084985 hasAuthorship W2898084985A5075417603 @default.
• W2898084985 hasAuthorship W2898084985A5085449385 @default.
• W2898084985 hasAuthorship W2898084985A5085499011 @default.
• W2898084985 hasAuthorship W2898084985A5089732639 @default.
• W2898084985 hasBestOaLocation W28980849851 @default.
• W2898084985 hasConcept C121608353 @default.
• W2898084985 hasConcept C126322002 @default.
• W2898084985 hasConcept C141071460 @default.
• W2898084985 hasConcept C143998085 @default.
• W2898084985 hasConcept C2775999482 @default.
• W2898084985 hasConcept C2776256026 @default.
• W2898084985 hasConcept C2776694085 @default.
• W2898084985 hasConcept C2776907518 @default.
• W2898084985 hasConcept C2777543607 @default.
• W2898084985 hasConcept C2777626846 @default.
• W2898084985 hasConcept C2777714996 @default.
• W2898084985 hasConcept C2777910003 @default.
• W2898084985 hasConcept C2777930144 @default.
• W2898084985 hasConcept C2778087573 @default.
• W2898084985 hasConcept C2778715236 @default.
• W2898084985 hasConcept C2779177807 @default.
• W2898084985 hasConcept C2779438470 @default.
• W2898084985 hasConcept C2781182431 @default.
• W2898084985 hasConcept C535046627 @default.
• W2898084985 hasConcept C61943457 @default.
• W2898084985 hasConcept C71924100 @default.
• W2898084985 hasConcept C81729549 @default.
• W2898084985 hasConceptScore W2898084985C121608353 @default.
• W2898084985 hasConceptScore W2898084985C126322002 @default.
• W2898084985 hasConceptScore W2898084985C141071460 @default.
• W2898084985 hasConceptScore W2898084985C143998085 @default.
• W2898084985 hasConceptScore W2898084985C2775999482 @default.
• W2898084985 hasConceptScore W2898084985C2776256026 @default.
• W2898084985 hasConceptScore W2898084985C2776694085 @default.
• W2898084985 hasConceptScore W2898084985C2776907518 @default.
• W2898084985 hasConceptScore W2898084985C2777543607 @default.
• W2898084985 hasConceptScore W2898084985C2777626846 @default.
• W2898084985 hasConceptScore W2898084985C2777714996 @default.
• W2898084985 hasConceptScore W2898084985C2777910003 @default.
• W2898084985 hasConceptScore W2898084985C2777930144 @default.
• W2898084985 hasConceptScore W2898084985C2778087573 @default.
• W2898084985 hasConceptScore W2898084985C2778715236 @default.
• W2898084985 hasConceptScore W2898084985C2779177807 @default.
• W2898084985 hasConceptScore W2898084985C2779438470 @default.
• W2898084985 hasConceptScore W2898084985C2781182431 @default.
• W2898084985 hasConceptScore W2898084985C535046627 @default.
• W2898084985 hasConceptScore W2898084985C61943457 @default.
• W2898084985 hasConceptScore W2898084985C71924100 @default.
• W2898084985 hasConceptScore W2898084985C81729549 @default.
• W2898084985 hasIssue "10" @default.
• W2898084985 hasLocation W28980849851 @default.
• W2898084985 hasOpenAccess W2898084985 @default.
• W2898084985 hasPrimaryLocation W28980849851 @default.
• W2898084985 hasRelatedWork W2761139746 @default.
• W2898084985 hasRelatedWork W2765285169 @default.
• W2898084985 hasRelatedWork W2779666206 @default.
• W2898084985 hasRelatedWork W3030077977 @default.
• W2898084985 hasRelatedWork W3093484307 @default.
• W2898084985 hasRelatedWork W3095217392 @default.
• W2898084985 hasRelatedWork W3108493759 @default.
• W2898084985 hasRelatedWork W3137075329 @default.
• W2898084985 hasRelatedWork W4318323499 @default.

• next